Proton beam therapy versus trans-arterial chemoembolization for BCLC stage B hepatocellular carcinoma—a propensity-matched analysis
Strahlentherapie und Onkologie · 2025
DOI: 10.1007/s00066-025-02495-9 ↗Kurz gefasst
Vergleichsstudie in der Zeitschrift Strahlentherapie und Onkologie, 2025. Verfasst von Tzu-Ting Liu und 11 weiteren Autor:innen. Beteiligte Einrichtung: Department of Radiation Oncology & Proton and Radiation Therapy Center, Kaohsiung Chang Gung Memorial Hospital, Chang Gung University College of Medi…. Hauptthemen laut MEDLINE: Liver Neoplasms, Carcinoma, Hepatocellular, Chemoembolization, Therapeutic, Proton Therapy. Die Arbeit nennt 38 Literaturangaben. Gefördert von: Chang Gung Memorial Hospital Research Project.
Abstract (Originalsprache)
PURPOSE: Proton beam therapy (PBT) has a promising local control rate, but clinical data supporting its use for intermediate-stage hepatocellular carcinoma (HCC) remains insufficient, and its survival benefit over transarterial chemoembolization (TACE) has yet to be established. This study aimed to compare the two modalities by evaluating real-world survival outcomes. METHODS: The propensity score-matched (PSM) cohort study used data from a multi-institutional medical research database. Treatment-naïve patients with Barcelona Clinic Liver Cancer (BCLC) stage B HCC who underwent PBT or TACE as monotherapy were enrolled. Baseline patient and tumor characteristics were used for matching. Overall survival (OS) and post-treatment albumin-bilirubin (ALBI) grade were assessed, and stratified analyses were performed to evaluate the heterogeneity. RESULTS: Between January 2007 and December 2022, 4349 patients with BCLC‑B HCC were identified, 1172 of whom met the inclusion criteria (PBT: 68; TACE: 1104). The PSM cohort matched 340 patients (PBT: 68; TACE: 272). Cox regression analysis revealed a significant survival benefit in the PBT group (p = 0.032, hazard ratio (HR) 0.64, 95% CI 0.42-0.97). Liver function was assessed in terms of ALBI grade every 3 months for 12 months after treatment, and the proportion of patients who maintained better liver function was greater in the PBT group than in the TACE group (p = 0.006). CONCLUSION: For patients with BCLC‑B HCC who are suitable candidates for PBT, PBT preserves better liver function than TACE and provides superior OS.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Radiation Oncology & Proton and Radiation Therapy Center, Kaohsiung Chang Gung Memorial Hospital, Chang Gung University College of Medicine, Kaohsiung, Taiwan.
- School of Medicine, College of Medicine, Chang Gung University, Taoyuan, Taiwan.
- Department of Radiation Oncology, Linkou Chang Gung Memorial Hospital and Chang Gung University College of Medicine, Taoyuan, Taiwan.
- School of Traditional Chinese, Chang Gung University, Taoyuan, Taiwan.
- Department of Radiation Oncology, Kaohsiung Chang Gung Memorial Hospital, School of Medicine, College of Medicine, National Sun Yat-Sen University, Kaohsiung, Taiwan.
- Department of Diagnostic Radiology, Kaohsiung Chang Gung Memorial Hospital and Chang Gung University College of Medicine, Kaohsiung, Taiwan.
Förderung
- Chang Gung Memorial Hospital Research Project
Zitieren
APA
Liu, T. T., Huang, B. S., Wang, Y. M., Liu, C. M., Huang, E. Y., Ou, H. Y., Hu, T. H., Lu, S. N., Hung, C. H., Chen, Y. H., Chen, C. S., & Cheng, J. Y. (2025). Proton beam therapy versus trans-arterial chemoembolization for BCLC stage B hepatocellular carcinoma—a propensity-matched analysis. Strahlentherapie und Onkologie. https://doi.org/10.1007/s00066-025-02495-9
Vancouver
Liu TT, Huang BS, Wang YM, Liu CM, Huang EY, Ou HY, et al. Proton beam therapy versus trans-arterial chemoembolization for BCLC stage B hepatocellular carcinoma—a propensity-matched analysis. Strahlentherapie und Onkologie. 2025. doi:10.1007/s00066-025-02495-9
BibTeX
@article{Liu2025,
author = {Liu, Tzu-Ting and Huang, Bing-Shen and Wang, Yu-Ming and Liu, Chieh-Min and Huang, Eng-Yen and Ou, Hsin-You and Hu, Tsung-Hui and Lu, Sheng-Nan and Hung, Chao-Hung and Chen, Yen-Hao and Chen, Chung-Shih and Cheng, Jen-Yu},
title = {Proton beam therapy versus trans-arterial chemoembolization for BCLC stage B hepatocellular carcinoma—a propensity-matched analysis},
journal = {Strahlentherapie und Onkologie},
year = {2025},
doi = {10.1007/s00066-025-02495-9}
}
EUVIMED